Anti-tumor effects of zoledronic acid-loaded stealth cationic liposome by targeting tumor angiogenesis

Abstract

Abstract:

AIM: To investigate the anti-tumor effect of APRPG modified zoledronic acid-loaded stealth cationic liposomes in nude mice bearing PC-3 prostate cancer. METHODS: Prostate cancer cell PC-3 beared nude mice model was constructed, growth inhibition of tumor volume between zoledronic acid cationic liposome and APRPG modificated zoledronic acid-loaded stealth cationic liposomes was compared, and the tumor inhibition rate was calculated. Immunohistochemistry analysis was used to detect the effect on expression of VEGF and CD44. RESULTS: The tumor inhibition rate of zoledronic acid cationic liposome and APRPG modificated zoledronic acid-loaded stealth cationic liposomes were 31.81%,68.18%, respectively, the tumor inhibition rate of the latter was significantly higher than that of the former (P<0.05), immunohistochemical results showed that VEGF and CD44 protein expression was strong positive in the model control group, in zoledronic acid cationic liposome group, it showed a moderate positive expression, and in APRPG modificated zoledronic acid-loaded stealth cationic liposomes group, the expression was very weak. CONCLUSION: The APRPG modified stealth liposome can exert a stronger inhibition effect in PC-3 nude mice.

Key words: targeting tumor angiogenesis, zoledronic acid-loaded stealth cationic liposomes, anti tumor

CLC Number:

R965.2

CHEN Fangjun, WANG Zeng, CAI Xinjun, CAO Yingying, CHEN Pei, SHAO Yun. Anti-tumor effects of zoledronic acid-loaded stealth cationic liposome by targeting tumor angiogenesis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 33-36.

References

［1］Zhao X, Hu X. Dosing of zoledronic acid with its anti-tumor effects in breast cancer［J］. J Bone Oncol, 2015, 4(3): 98-101.
［2］Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients［J］. Clin Cancer Res, 2003, 9(8): 2893-2897.
［3］Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates［J］. J Transl Med, 2011, 9: 177.
［4］De Luca A, Lamura L, Gallo M, et al. Pharmacokinetic evaluation of zoledronic acid［J］. Expert Opin Drug Metab Toxicol, 2011, 7(7): 911-918.
［5］Riebeline C, Forsea AM, Raisova M, et al.The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro［J］. Br J Cancer, 2002, 87(3): 366-371.
［6］Lu ZX, Liu LT, Qi XR. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy［J］. Int J Nanomedicine, 2011, 6: 1661-1673.
［7］Cai XJ, Wang Z, Wang CY, et al. In vitro and in vivo evaluation of cationic liposomes containing zoledronic acid as anticancer agent［J］. Latin Am J Pharm, 2015, 34(6): 1239-1245.
［8］Honda M, Asai T, Oku N, et al. Liposomes and nanotechnology in drug development: focus on ocular targets［J］. Int J Nanomedicine, 2013, 8: 495-503.
［9］Wang Y, Liu P, Duan Y, et al. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer［J］. Biomaterials, 2014, 35(3): 983-992.
［10］Barbera-Guillem E, Nyhus JK. Vascular endothelial growth factor secretion by tumor- infiltrating macrophages essentially supports tumor angioge- nesis, and IgG immune complexes potentiate the process［J］. Cancer Res, 2002, 62 (23): 7042-7049.
［11］Bozorgi A, KhazaeiI M, Khazaei MR. New findings on breast cancer stem cells: a review［J］. J Breast Cancer, 2015, 18(4): 303-312.

[1]	CAO Xuefen, LENG Yufang, HAN Xiaoxia, HOU Xiaoyu, LYU Xingjiao, Janvier NIBARUTA. Tetramethylpyrazine protected against intestinal ischemia-reperfusion injury induced pyroptosis by inhibiting NLRP3 inflammasome activation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1201-1208.
[2]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[3]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[4]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[5]	SHI Dandan, SUN Yiyao, CHEN Xiaoqi, YANG Fangming, ZHANG Chuanlei, WANG Xinting, YUAN Changwei, CHEN Xinju. Curative effect of fuzheng xiaoliu granules in the treatment of primary liver cancer and analysis of serum metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1247-1262.
[6]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[7]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[8]	HENG Bingbing, YANG Danfeng, DAI Shuyang, SHANGGUAN Wangning. Propofol relieves the subcutaneous chloroquine-induced pruritus in rats via TRPV1 and CB1 receptors of spinal cord [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1101-1108.
[9]	LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
[10]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[11]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[12]	MAO Jun, RONG Yu, LI Yangen, XIONG Dengxi, ZHAO Peng, ZHA Zhengjiang. Effect and safety of flurbiprofen axetil in the analgesic treatment of patients with craniocerebral injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1056-1060.
[13]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[14]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[15]	LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.